Vaxil Bio is a cutting-edge Israeli biotech focused on immuno-oncology as innovative cancer treatments.
Vaxil's lead product, Immucin, has recently been granted "Orphan Drug Status" from both the FDA and the EMA agencies.
Vaxil is based out of the Weizmann Science Park, Israel's top scientific institution, and was founded by Weizmann PhD Dr. Lior Carmon.
The Company has completed a highly successful Phase-I/II in 15 Mutiple Myeloma patients, wherein 100% demonstrated robust immune responses, the results of which were published in the British Journal of Haematology
Vaxil's patented platform, VaxHit, will protect the Company's ability to develop further cancer immunotherapy products utilizing the signal peptide domain of MUC1 which is present in 90% of cancers.
Please visit www.vaxil-bio.com for more information
Company Details
- Employees
- 4
- Founded
- 2007
- Address
- Pinchas Sapir 3, Weizmann Science Park,israel
- in****@****bio.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- vxlbio.com
- HQ
- Rehovot
Vaxil Bio Ltd. Questions
Vaxil Bio Ltd.'s website is vxlbio.com
Vaxil Bio Ltd.'s LinkedIn profile is https://il.linkedin.com/company/vaxil-bio-ltd.
Vaxil Bio Ltd. has
4 employees.
View email and phone details for 4
employees at Vaxil Bio Ltd..
Vaxil Bio Ltd.'s industry is
Biotechnology Research
Vaxil Bio Ltd.'s top competitors are
Bio-Team Medical Ltd,
Mndl Bio,
Vaxil For Pharmaceutical Industries,
Nucleix Ltd.,
Meir Science Technologies Ltd.,
Ophrx,
Briacell Therapeutics Corp.,
Neotx Therapeutics Ltd,
1e Therapeutics,
Vbl Therapeutics (Nasdaq:vblt).
Vaxil Bio Ltd.'s support email address is info@vaxilbio.com
Vaxil Bio Ltd.'s categories are Biotechnology Research
Vaxil Bio Ltd.'s founding year is 2007
